Karen Reckamp, MD, MS: Results in Phase II Advanced Lung Cancer Trial
Description: Dr. Karen Reckamp reports on the analysis of pre-treatment serum samples from a Phase II study evaluating erlotinib (Tarceva) or erlotinib plus high-dose celecoxib (Celebrex) in advanced non-small cell lung cancer (NSCLC) patients at the 2012 Multidisciplinary Symposium in Thoracic Oncology in Chicago.
Karen Reckamp, MD, MS works at the City of Hope Comprehensive Cancer Center when she is a Member, Developmental Cancer Therapeutics Program, Comprehensive Cancer Center -- Associate Professor of Medical Oncology and Co-chair, Lung Cancer and Thoracic Oncology; Medical Oncology, Lung Cancer and Thoracic Oncology Program
Shared By : vitaloptions
Posted on : 10/21/12
Added : 6 years ago